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burdens, i.e., HRQoL decrements, for the 31 conditions as mea-
sured by the EQ-5D US ranged from −0.002 to −0.195 on this
scale. Modeling disease-burden from other systems to the EQ-
5D US exhibited excellent ﬁt (R2 all > 0.85). When tested in
MEPS, the predicted disease-burdens in the EQ-5D US were
slightly biased (0.0012 from SF-6D(12), 0.0083 from EQ-5D
UK). Tested in USVEQ data, the predicted disease-burdens for
the EQ-5D US were more biased (0.0125 from HUI Mark 2,
0.0144 from HUI Mark 3). The standard deviation of differences
between predicted and actual disease-burdens was around 0.01
for most measures. CONCLUSION: This method produces rel-
atively unbiased estimates for disease-burden across HRQoL
scoring systems. Current error variance associated with this
method limits its usability. Future work should examine non-
linear cross-walks between HRQoL scores.
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OBJECTIVES: To elicit preferences for the spectrum of health
states associated with Stage III colon cancer (CRC) and to
explore the effect of neuropathy associated with current stan-
dard of care for adjuvant treatment. METHODS: We inter-
viewed CRC patients and clinicians, developed health states and
used time trade-off (TTO) to elicit preferences from a conve-
nience sample of CRC patients and community members. We
elicited preferences for 7 health states: remission (REM); adju-
vant therapy with no (ADJ_NO), mild (ADJ_MLD), moderate
(ADJ_MOD), and severe (ADJ_SEV) neuropathy; metastatic
stable (MET_ST); and metastatic progressive (MET_PR) disease.
Each subject valued a randomly selected subset of 5 health states.
T-tests were used to test for differences in preferences. RESULTS:
Mean ages of the 49 patients and 49 community members were
60.6 and 59.8 years, respectively. 51% and 57% were male,
respectively. Mean TTO values (95% CIs) for patients/commu-
nity members were: REM 0.87 (0.81, 0.93)/0.83 (0.77, 0.89);
ADJ_NO 0.67 (0.55, 0.80)/0.62 (0.50, 0.74); ADJ_MLD 0.65
(0.49, 0.82)/0.52 (0.39, 0.65); ADJ_MOD 0.58 (0.40, 0.76)/0.48
(0.35, 0.61); ADJ_SEV 0.48 (0.30, 0.65)/0.35 (0.22, 0.49);
MET_ST 0.46 (0.30, 0.62)/0.54 (0.42, 0.65); MET PR 0.38
(0.21, 0.56/0.21 (0.09, 0.34). Signiﬁcant differences were
observed for both groups between TTO for REM and adjuvant
health states and between ADJ_NO and metastatic health states
(p < 0.04), except for ADJ_NO vs. MET_S within the patient
group. There was a non-signiﬁcant trend for patients to place a
higher TTO value on all health states than community members
(p = 0.20). CONCLUSION: These ﬁndings highlight the trade-
offs between the disutility of adjuvant treatment (particularly
with moderate to severe neuropathy) and the higher utility of
remission, and the severe utility loss during metastatic disease.
The preference values obtained from this study will be useful for
informing cost-utility analyses of treatment through progression
of colon cancer.
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OBJECTIVES: To identify theoretical and methodological chal-
lenges to valuing children’s health for cost-utility or beneﬁt-
cost analysis. METHODS: We reviewed the most common
approaches, quality-adjusted life years and willingness-to-pay
values, for valuing health in economic evaluations and consid-
ered methodological and practical issues associated with mea-
suring child health using each framework. RESULTS: The review
of theoretical and practical challenges suggests that both areas
pose challenges to valuing child health. Practical challenges
include elicitation issues and the consideration of household
effects of child illness. One challenge is the inability of young
children to value changes in health directly and the potential
biases associated with using proxy respondents. The most appro-
priate elicitation method will vary by age of the child under con-
sideration. Another key challenge arises from the status of
children not as independent economic actors, but as being depen-
dent on others for care and decision making. In addition, illness
in children may also affect parent/caregiver quality-of-life further
complicating the measurement of value associated with the
change in a child’s health status. From a theoretical perspective,
“value of a child’s health” has not yet been adequately deﬁned
if one accepts that many children are insufﬁciently mature to
have informed, considered preferences over health states. CON-
CLUSION: Recommendations for moving the ﬁeld forward in
valuing child health for economic evaluations will vary by age;
a “one size ﬁts all” approach does not readily ﬁt. Future research
should focus on minimizing bias from proxy respondents, con-
sideration of a family or household-based approach to valuing
health effects, and development of generic instruments for chil-
dren with age-appropriate domains.
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OBJECTIVE: Appropriate utilization of diabetes medications is
key to improving clinical and ﬁnancial effects of the disease.
Pharmacy beneﬁts may contain barriers to patients utilizing these
medications. This study assessed the impact of elimination of
member cost share and other beneﬁt barriers on utilization of
diabetes medications. METHODS: Study used a pre-post com-
parison of 1281 individuals whose pharmacy beneﬁts were pro-
vided by an employer that eliminated beneﬁt barriers (member
cost, reﬁll restrictions, prior authorization) on 1/1/2006. Eligible
study participants had continuous eligibility for pharmacy ben-
eﬁts from 1/1/2005 through 12/31/2006 and ﬁlled prescriptions
for diabetes medication both before and after the beneﬁt design
change date. Adherence to therapy was measured by a weighted
average of the therapeutic class Medication Possession Ratio
(MPR) and was calculated during the period prior to the beneﬁt
change (January 1, 2005–December 31, 2005) and following it
(January 1, 2006–December 31, 2006). RESULTS: Study popu-
lation was 45% female (mean age 46.6). Subsequent to beneﬁt
design change, MPR increased by 2.0% (78.2% to 80.2%; p-
value = 0.003) for core diabetic therapy (insulin, sulfonylureas,
metformin or combinations). Proportion of members with
optimal adherence (80% or more MPR) increased from 58.6%
to 64.9% (p-value < 0.001). Average number of prescriptions per
member did not change (11.7 vs. 11.7; p-value = 0.95), but days
supply increased signiﬁcantly (362 days vs. 459 days; p-value <
0.001) with no detectable increase in mail utilization. Proportion
of members using adjunct therapy (glucosidase inhibitors, amylin
